|
Volumn 34, Issue 24, 2016, Pages 2935-2936
|
Critique of the American society of clinical oncology value assessment framework for cancer treatments: Putting methodologic robustness first
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
CANCER PALLIATIVE THERAPY;
CANCER SURVIVAL;
CONCEPTUAL FRAMEWORK;
DISEASE FREE SURVIVAL;
DRUG RESPONSE;
DRUG SAFETY;
HUMAN;
LETTER;
NEOPLASM;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ONCOLOGY;
UNITED STATES;
HUMANS;
MEDICAL ONCOLOGY;
NEOPLASMS;
UNITED STATES;
|
EID: 84982112064
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2015.64.9673 Document Type: Letter |
Times cited : (15)
|
References (4)
|